Jul 29, 2021
Arundhati interviewed Sarah Boyce, CEO of Avidity Biosciences.
In October 2019, Sarah Boyce joined Avidity as President and CEO,
and she serves as a member of the board of directors. Ms. Boyce
brings to Avidity extensive operational, commercial and leadership
experience in the life sciences industry and has built global
organizations, bringing a number of innovative therapies including
Tegsedi®, Waylivra®, Soliris®, Gleevec® and Tasigna® to
patients.
Episode Resources